Filing Details

Accession Number:
0001415889-23-001209
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-19 17:07:31
Reporting Period:
2023-01-17
Accepted Time:
2023-01-19 17:07:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1159036 Halozyme Therapeutics Inc. HALO Biological Products, (No Disgnostic Substances) (2836) 880488686
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1528185 Helen Torley C/O Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego CA 92130
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-17 10,000 $14.66 597,177 No 4 M Direct
Common Stock Disposition 2023-01-17 8,897 $50.40 588,280 No 4 S Direct
Common Stock Disposition 2023-01-17 1,103 $50.93 587,177 No 4 S Direct
Common Stock Acquisiton 2023-01-18 10,000 $14.66 597,177 No 4 M Direct
Common Stock Disposition 2023-01-18 10,000 $51.05 587,177 No 4 S Direct
Common Stock Acquisiton 2023-01-19 10,000 $14.66 597,177 No 4 M Direct
Common Stock Disposition 2023-01-19 10,000 $52.41 587,177 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock Disposition 2023-01-17 10,000 $14.66 10,000 $14.66
Common Stock Option to Purchase Common Stock Disposition 2023-01-18 10,000 $14.66 10,000 $14.66
Common Stock Option to Purchase Common Stock Disposition 2023-01-19 10,000 $14.66 10,000 $14.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
80,000 2024-01-06 No 4 M Direct
70,000 2024-01-06 No 4 M Direct
60,000 2024-01-06 No 4 M Direct
Footnotes
  1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 7, 2022 in accordance with Rule 10b5-1.
  2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $49.89 to $50.85. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.89 to $50.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.75 to $51.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.13 to $52.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.